Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios

Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases.